Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma

Bone Marrow Transplantation volume 29, pages S14–S17 (2002)Cite this article

Abstract

The long median survival time of patients with follicular non-Hodgkin's lymphoma (NHL), means that the efficacy of new treatments are difficult to assess in the short term. Bcl-2 is an inhibitor of apoptosis and overexpression of the bcl-2 gene in the blood or bone marrow is a feature in up to 85% of patients with follicular NHL. Levels of bcl-2+ cells in the peripheral blood or bone marrow therefore are a useful measure of disease status in such patients and can be detected by polymerase chain reaction (PCR). Complete bcl-2 clearance from the bone marrow (molecular remission) following autologous stem cell transplant (ASCT) for follicular NHL is considered to be an important prognostic factor for disease-free survival. Tumour cell contamination of the stem cell grafts used in ASCT is commonly associated with relapse. This can be addressed by purging the stem cell harvest prior to transplantation. Various methods of in vitro purging after stem cell collection have been shown to reduce the level of contamination but yield is invariably reduced and grafts remain bcl-2 positive. However, in vivo purging with rituximab during the process of collection has been used to obtain bcl-2-negative stem cell harvests without compromising the yield. Rituximab is a monoclonal antibody licensed for treatment of relapsed and refractory low-grade or follicular NHL. Rituximab targets the CD20 antigen, which is found on cells of the B cell lineage. When used for in vivo purging it depletes the peripheral blood of CD20-positive cells and prevents contamination by lymphoma cells. Molecular remission, as measured by bone-marrow bcl-2 clearance, has been achieved in 7/7 patients with follicular NHL at 1 year after treatment with ASCT using rituximab as an ‘in vivopurse’, followed by rituximab maintenance. Early clinical outcomes are also encouraging.

Bone Marrow Transplantation (2002) 29, Suppl. 1, S14–S17. doi:10.1038/sj.bmt.1703297

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphomas New Engl J Med 1984 311: 1471 1475

    Article  CAS  PubMed  Google Scholar 

  2. Baldini L, Guffanti A, Gobbi P et al. A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi Cancer 1997 79: 1234 1240

    Article  CAS  PubMed  Google Scholar 

  3. Hagenbeek A, Eghbali H, Monfardini S et al. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade non-Hodgkin's lymphoma. Preliminary results from a prospective randomized phase III clinical trial in 381 patients Blood 1998 92: 315a

    Google Scholar 

  4. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275 3280

    CAS  PubMed  Google Scholar 

  5. Berinstein NL, Reis MD, Ngan BY et al. Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma J Clin Oncol 1993 11: 1344 1352

    Article  CAS  PubMed  Google Scholar 

  6. Liu Y, Hernandez AM, Shibata D et al. BCL2 translocation frequency rises with age in humans Proc Natl Acad Sci USA 1994 91: 8910 8914

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chao DT, Korsmeyer SJ . BCL-2 family: regulators of cell death Annu Rev Immunol 1998 16: 395 419

    Article  CAS  PubMed  Google Scholar 

  8. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma Blood 1999 94: 3325 3333

    CAS  PubMed  Google Scholar 

  9. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas Blood 1998 91: 2955 2960

    CAS  PubMed  Google Scholar 

  10. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series Ann Oncol 2000 11 (Suppl. 1): 137 140

    Article  Google Scholar 

  11. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825 2833

    Article  CAS  PubMed  Google Scholar 

  12. Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy Ann Oncol 2001 12: 109 114

    Article  CAS  PubMed  Google Scholar 

  13. Gribben JG, Neuberg D, Barber M et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow Blood 1994 83: 3800 3807

    CAS  PubMed  Google Scholar 

  14. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood 1993 81: 3449 3457

    CAS  PubMed  Google Scholar 

  15. Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems Stem Cells 1997 15: 297 304

    Article  CAS  PubMed  Google Scholar 

  16. Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation – results of a retrospective analysis on 120 patients autografted in a single institution J Clin Oncol 1998 16: 2803 2816

    Article  CAS  PubMed  Google Scholar 

  17. Horning JS . Investigation of monoclonal antibody therapy with conventional and high-dose treatment: current clinical trials Semin Hematol 2000 37 (4 Suppl. 7): 27 33

    Article  Google Scholar 

  18. Anderson KC, Bates MP, Slaughenhoupt BL et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation Blood 1984 63: 1424 1433

    CAS  PubMed  Google Scholar 

  19. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 1994 83: 435 445

    CAS  PubMed  Google Scholar 

  20. Shan D, Ledbetter JA, Press OW . Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 1998 91: 1644 1652

    CAS  PubMed  Google Scholar 

  21. Coiffier B, Lepage E, Herbrecht R et al. MabThera (rituximab) plus CHOP is superior to chop alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial Blood 2000 96: 950a

    Google Scholar 

  22. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol 1999 17: 268 276

    Article  CAS  PubMed  Google Scholar 

  23. Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 1994 84: 2457 2466

    CAS  PubMed  Google Scholar 

  24. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by ‘in vivo purging’ with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol 1999 5 (Suppl. 14): 115 122

    Google Scholar 

  25. Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts) Blood 1999 94 (Suppl. 1): 141a

    Google Scholar 

  26. Haioun C, Delfau-Larue MH, Beaujean F et al. Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (PBSCT) in B-cell non-Hodgkin's lymphomas (NHL). A single institution study Blood 2000 96: 384a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Therapeutics Program, Toronto-Sunnybrook Regional Cancer Centre and Sunnybrook and Women's College Health Centre, Toronto, Ontario, Canada

    NL Berinstein, R Buckstein, K Imrie, D Spaner, J Mangel, K Tompkins, N Pennell, M Reis, P Pavlin, A Lima, A Couvadia, J Robinson & P Richardson

Authors
  1. NL Berinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Buckstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Imrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Spaner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Mangel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Tompkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Pennell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P Pavlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Couvadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P Richardson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to NL Berinstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berinstein, N., Buckstein, R., Imrie, K. et al. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. Bone Marrow Transplant 29 (Suppl 1), S14–S17 (2002). https://doi.org/10.1038/sj.bmt.1703297

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703297

Keywords

This article is cited by

Search

Advanced search

Quick links